The mammalian Target of Rapamycin (mTOR) is a serine/threonine kinase which regulates cell growth, proliferation, metabolism and cell survival, and plays those roles by forming two functionally distinct multiprotein complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2).
Introduction
Multiple myeloma (MM) is a malignant plasma cell disorder, characterized by an abnormal accumulation of plasma cells (PCs) in the bone marrow. As a consequence, bone lesions are generated and, in many cases, over-production of paraprotein/antibodies may cause kidney dysfunction (1) . The introduction of new agents such as the proteasome inhibitor bortezomib or the thalidomide analog lenalidomide in the treatment of myeloma patients has resulted in improved response rates and longer overall survival (2) (3) (4) (5) . However, most patients eventually relapse, making this malignancy incurable. For these reasons, the development of novel therapies is absolutely required in order to provide more treatment options.
Mammalian Target of Rapamycin (mTOR) is a kinase that regulates cell growth, survival, proliferation and metabolism (6) . mTOR functions by forming two protein complexes, mTORC1 and mTORC2, that share common proteins like mTOR, mLST8, and DEPTOR, but also contain complex-specific components, as is the case of Raptor and PRAS40 for mTORC1, and Rictor, mSin1 and Protor1/2 for mTORC2, respectively (7) . As for the downstream effectors of these complexes, S6 kinases (S6Ks) and eIF4E-binding proteins (4E-BPs) are well identified mTORC1 downstream targets (7, 8) . The kinases S6K1 and S6K2 are members of the S6Ks family, which enhance the mRNA translation by phosphorylation and activation of ribosomal protein S6 (S6) and eIF4B. The 4E-BP family includes 4E-BP1, 4E-BP2 and 4E-BP3 which function as translational repressors through binding to eIF4E, a protein required for the assembly of the translation machinery. mTORC1 may phosphorylate and prevent 4E-BPs from binding to eIF4E and thereby enhance the cellular mRNA translation (9) . On the other hand, several members of the AGC subfamily of kinases including Akt and the serum-and glucocorticoid-regulated kinase 1 (SGK1) have been identified as mTORC2 specific substrates that regulate cell survival, growth and metabolism (7, 8) . mTORC2 directly phosphorylates Akt at Ser473 and such phosphorylation is required for its maximal activation (10) .
Several lines of evidence indicate that targeting the mTOR pathway may represent an efficient strategy against MM. Activation of Akt has been reported in a substantial proportion of plasma cells from MM patients, and may be linked to the progression of the disease (11) . In addition, overexpression of DEPTOR in MM is a frequent event and its down regulation by gene knockdown results in impaired growth of MM cells (12) .
Several types of mTOR inhibitors have been used in the clinic (13) . Rapamycin and its analogs were the first generation of mTOR inhibitors. These allosteric inhibitors were initially used in transplantation as immunosuppressant drugs and have been approved in several oncology settings such as advanced renal cell carcinoma, pancreatic neuroendocrine tumors, advanced breast cancer or acute myeloid leukemia (14, 15) . These rapalogs influence the mTOR pathway by binding to FKBP12 (FK506-binding protein of 12 kDa). Subsequently, the resulting rapamycin-FKBP12 complex interacts with mTOR FRB (FKBP12-rapamycin binding) domain and interferes with the binding of Raptor to mTOR (16) . However, recent studies indicated rapalogs lack of efficacy in several contexts which may be related to the rapamycin-insensitive mTOR actions (15) . Thus, while in some cell lines prolonged treatment with rapamycin may block mTORC1 and mTORC2 complexes (17) , in other cell types rapamycin does not affect mTORC2 signaling. Moreover, rapamycin may provoke Akt activation in some cells, probably caused by a negative feedback exerted by mTORC1 over mTORC2 (18) (19) (20) . In addition, in some cell types rapamycin fails to affect the phosphorylation of 4E-BP1 (18, 21) , raising doubts about the capacity of the drug to act as an efficient mTORC1 inhibitor. In order to overcome the inefficacy of rapamycin, a new type of active-site mTOR inhibitors, also known as second generation mTOR inhibitors, are being developed (13, (22) (23) (24) . These inhibitors directly target the ATP-binding site of mTOR, blocking its catalytic activity and were found to be able to completely inhibit the mTOR pathway. Nevertheless, their use and advantage over first generation mTOR inhibitors in the myeloma context needs to be studied.
Through analysis of gene expression as well as cytometric and biochemical data, we show here that deregulation of mTOR pathway is a frequent event in MM. Moreover, by using a genetic approach, we have evaluated the relevance of targeting mTORC1, mTORC2 or acting on both mTOR-derived routes as an antimyeloma strategy. These experiments revealed predominance of mTORC1 over mTORC2 in controlling malignant plasma cell proliferation. However, a better anti-proliferative action was obtained when total mTOR activity was downregulated, as compared to exclusively acting on mTORC1 or mTORC2. Finally, we validated the possibility of targeting mTOR pathway using different mTOR inhibitors available in the clinic on preclinical MM models. The anti-Protor-1, anti-GAPDH, anti-Cyclin E, anti-CDK2, anti-PARP, anti-AIF and anti-p27
antibodies were purchased from Santa Cruz Biotechnology. The anti-mTOR, anti-Raptor, anti-COX IV,
anti-S6, anti-pS6 (S240/244), anti-p4E-BP1 (T37/46), anti-Akt and anti-pS6 (S235/236)-Alexa488
antibodies were from Cell Signaling Technologies. The anti-active-caspase-3, anti-caspase-3, anti-Rb, anti-Smac, anti-cytochrome c, anti-Cyclin A, anti-pAkt (S473)-PE, anti-CD19-PerCP-Cy5.5 and anti-CD38-APC were obtained from BD Biosciences. The anti-DEPTOR, anti-mLST8 and anti-Sin1 antibodies were from Millipore Corporation. The anti-Rictor was from Bethyl laboratories. The anti-pAkt (S473) antibody was generated in the laboratory and has already been described (25) .
Patient samples
The detection of mTOR pathway activation on patient samples was carried out by flow cytometry.
That study included patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma diagnosed according to the International Myeloma Working Group (IMWG) criteria (26) . Samples were collected after informed consent in accordance to the Declaration of Helsinki, and with the approval from the ethical committee of the local university hospital.
Cell lines and culture, transfections, generation of lentiviruses and infection
The HEK-293T and the human stromal cell line HS-5 were obtained from the ATCC and maintained at low passages. All the human multiple myeloma cell lines used were obtained in 2003 as described (27, 28 ) and maintained at low passages. No authentication of the myeloma cell lines was done by the authors.
HEK-293T cells were grown in DMEM medium and all the other cells in RPMI1640 medium both supplemented with 10% FBS and antibiotics. All cells were cultured at 37°C in a humidified atmosphere in the presence of 5% CO 2 -95% air. The lentiviral vectors containing shRNA for Raptor, Rictor and mTOR have already been described (10, 18) and obtained from Addgene. For the production of lentiviruses, vectors were cotransfected in HEK-293T cells with the pMDLg/RRE, pRSV-Rev and pMD2.G plasmids by JetPEI TM transfection using a previously described protocol (27) . 48 hours after the transfection, the lentivirus-containing supernatants were filtered and either used to infect target cells or stored at -80ºC in aliquots. For the infection, target myeloma cells were incubated with the lentiviruses in the presence of 8 μg/ml polybrene. Two days after the infection, cells were selected with puromycin.
Detection of intracellular phospho-antigens by multi-color flow cytometry
The detection of phospho-antigens by flow cytometry was based on previous works (29) with some modifications. Briefly, cells were collected, fixed in 2% paraformaldehyde (PFA), permeabilized in 50%
ice-cold methanol/PBS and stained with the adequate phospho-specific antibodies and, if necessary, anti-surface lineage antibodies. For patient samples staining, whole bone marrow samples were fixed by adding 10% PFA. After washing out the PFA, samples were incubated in 0.1% Triton X-100 to remove the red blood cells. The remaining cells were then incubated in 50% methanol/PBS and stained with the combination of antibodies pS6-Alexa488, pAkt-PE, CD19-PerCP-Cy5.5 and CD38-APC. As a negative control, phospho-specific antibodies were competed with their corresponding phospho-peptides before the staining. Data were acquired using a FACScalibur flow cytometer (BD Biosciences). The same number of cells (100,000) was acquired for each sample.
Immunoprecipitation, Western blotting and cell fractionation
To prepare cells for protein analyses, they were collected by centrifugation, washed in PBS and lysed in ice-cold lysis buffer. Immunoprecipitation experiments, SDS-PAGE and Western Blot were performed as described (18) . Cell fractionation experiments were carried out following previously published indications (30) . 
Ex vivo evaluation of drugs on patient cells
The effect of drugs on primary patient samples was performed in an ex-vivo model as described (32) .
Briefly, once red blood cells were removed, myeloma patient bone marrow cells were plated and incubated in the presence of the drugs for 2 days. The cell mixture was collected and stained with the combination of anti-Annexin-V FITC, 7-AAD and anti-CD38-APC to evaluate the effect of the treatment on plasma cells (CD38+) by flow cytometry. On another set of experiments, FITC BrdU Flow Kit was used to detect BrdU incorporation specifically in plasma cells according to the provider instructions.
Gene expression analyses
For gene expression analysis a dataset from the Mayo Clinic, obtained through the Multiple Myeloma Genomics Portal (MMGP), was used (33) . The RMA-normalized, log2-transformed expression values were directly loaded into the R environment for further analysis (http://www.R-project.org) (34) . We mapped the genes of interest with the probe set IDs through NetAffy (Affymetrix). Finally, the extracted expression matrix corresponding to the mTOR pathway related genes in patients was obtained for further 
Statistical analyses
Two-sample t-test was used to compare the differences of mean between the two groups. Fisher´s exact test was applied on 2 × 2 contingency table to compare the differences of probability. Significant difference was considered when p < 0.05. All the statistical analyses were performed in the statistical software SPSS 15.0 (SPSS Inc). 
Results

Progressive deregulation of the mTOR pathway along the stepwise development of MM
We analyzed the expression levels of mTOR pathway related genes using a publically available microarray dataset (33) during the evolution of myeloma. A similar tendency in the V-ATPase ATP6V1G1, transcriptionally regulated by mTORC1 (35), was also observed. Besides, a decrease of Grb10, a recently discovered negative regulator of mTORC1, was detected between donors and MM (36) . A statistically significant increase in MM as compared to healthy donors was observed for DEPTOR, whose overexpression leads to activation of Akt in myeloma (12) , and S6K2 which is described to be upstream of S6 protein and regulated by mTORC1 (8) . No major changes in mTORC2 pathway components were detected (data not shown).
Activation of mTORC1 and mTORC2 in malignant plasma cells
To evaluate the activation status of mTORC1 and mTORC2 in MM, we utilized a flow cytometry approach to detect the phosphorylation of proteins used as surrogate markers of the activity of both mTOR branches. Such an approach was necessary due to the relative low number of PCs in the bone marrow. We initially optimized the use of monoclonal antibodies recognizing phosphorylated S6 and Akt in the myeloma cell line OPM-2. Using peptide competition, we confirmed the validity and specificity of the antibodies (Supplementary Figure 1A) . The workflow of the data analysis (Supplementary Figure 1B When each marker was individually analyzed, we found higher frequency of S6 activation in MM patients than in MGUS patients (67% vs 38% positive cases, Figure 1B) . Similarly, increased activation was observed for Akt (38% vs 25%) in myeloma PCs with respect to MGUS PCs. However, no statistical significance is reached between the two groups (p > 0.05 for both cases, fisher's exact test), which could be due to the low case number for MGUS. Unavailability of SMM samples prevented us from evaluating the levels of these phosphoproteins in this group of patients.
When both mTORC1 and mTORC2 substrates were considered together, we found that 71% of the patients harbored activation of the mTOR pathway, as indicated by the positive staining of phospho-S6 or phospho-Akt (Supplementary Figure 1D) . mTORC1 activation was more frequent, as indicated by the presence of the phosphorylation of S6 when compared with mTORC2 activation, measured by the presence of Akt phosphorylation (62% vs 33%, p = 0.016 by fisher's exact test, Supplementary figure 1D).
No correlation between positivity of Akt and pS6 was observed, suggesting the non-redundant function of mTORC1 and mTORC2 routes.
In the bone marrow samples from some MM patients, the residual normal PCs identified by CD19+/CD38+ staining were detectable, allowing comparison of the activation status of mTORC1 and mTORC2 among normal and malignant PCs from the same individual. In normal PCs from 17 patients the frequency of positive staining of pS6 was much lower than in their malignant counterparts (12% vs 65%, p = 0.004 by fisher's exact test, Figure 1C ). No activation of Akt was observed in normal PCs (data not shown). These data suggest that the activation of the mTOR pathway is more restricted to malignant PCs.
The mTOR pathway controls the proliferation of myeloma cells
The finding that the mTOR pathway was active in a substantial number of MM patients prompted us to analyze the importance of this route in MM. Western blot analyses of the different components of the mTORC1 and mTORC2 pathways indicated that they were all expressed in MM cell lines (Figure 2A ). To analyze the activation of mTORC1 and mTORC2 in the different cell lines, we evaluated S6 and Akt phosphorylation as readouts of mTORC1 and mTORC2 activities, respectively. Phosphorylation of S6 was more frequently observed than that of Akt, corroborating what we observed in patient PCs (Figure 2A ).
To analyze the importance of the mTOR pathway in myeloma cells, we used RNA interference Raptor knockdown also resulted in a decrease in cell proliferation although to a lesser extent than mTOR knockdown in MM1S, while its knockdown had almost similar effect as mTOR knockdown in OPM-2.
Rictor diminution also reduced proliferation. Combined knockdown of raptor and rictor had a higher antiproliferative effect than the individual knockdowns, especially in the OPM2 cell lines. In this latter cell line, the combined rictor and raptor knockdown had a strong antiproliferative effect, of a magnitude analogous to the mTOR knockdown. Similar results were obtained by using a second set of shRNAs (data not shown).
Allosteric and active-site mTOR inhibitors differentially affect myeloma cell growth
The above data indicated that mTOR signaling plays a relevant role in the control of MM cell number.
Moreover, the knockdown data suggested that mTOR targeting may be more efficient as an anti-myeloma therapy than exclusively acting on mTORC1. To further study this possibility, we tested the effect of mTOR inhibition on myeloma preclinical models using both allosteric and active-site mTOR inhibitors.
We focused on a new-generation active-site mTOR inhibitor, CC214-1. This inhibitor exerts selectivity for mTOR over other related kinases such as PI3Kα (37) . We also used rapamycin, a classic allosteric mTORC1 inhibitor, whose action was compared to that of CC214-1.
CC214-1 substantially decreased MTT metabolization in all the myeloma cell lines tested, although more efficiently in MM1S, MM1R, OPM-2, NCI-H929 and SJR ( Figure 3A) . We also compared the efficacy of CC214-1 with rapamycin in MM1S and OPM-2 cells. Very low concentrations of rapamycin had a clear effect on cell growth, but it reached a plateau for cell growth inhibition, leaving more than 30% of cells unaffected ( Figure 3B ). However, CC214-1 almost completely inhibited the cell growth in these two cell lines, although at higher concentrations. 
CC214-1 inhibits proliferation of MM cells in co-culture with bone marrow stromal cells
The microenvironment plays a pivotal role in the control of the survival and proliferation of malignant PCs in myeloma patients, and contributes to drug resistance (38) . Therefore, we tested the effect of CC214-1 in an in vitro co-culture model that mimicked the bone marrow microenvironment. The effect of CC214-1 on MM1S or OPM-2 cell lines cultured on HS-5 stromal cells was similar to the above described MTT data ( Figure 3C ), indicating that CC214-1 overcomes the proliferative/protective advantage induced by stromal cells. Moreover, no cytotoxic effect was observed on HS-5 cells even at high concentrations, suggesting specificity of this drug for the myeloma cells.
mTOR pathway inhibition in myeloma cells provokes cell cycle arrest
Subsequently, we compared the effect of those mTOR inhibitors (rapamycin and CC214-1) on the mTOR pathway. CC214-1 completely inhibited the phosphorylation of S6, 4E-BP1 and Akt in MM1S or OPM-2; however, rapamycin inhibited the phosphorylation of S6 but not that of 4E-BP1 ( Figure 3D ). In contrast, rapamycin treatment caused an increase in pAkt. In addition, we observed that CC214-1 did not affect the MAPK pathway, another major route controlling cell growth and proliferation (data not shown).
To further explore the mechanism of action of mTOR inhibition on myeloma cell survival and proliferation, the cell cycle profile of cells treated with CC214-1 was analyzed. A clear G 0 /G 1 arrest was observed in the cell lines tested at a concentration of CC214-1 up to 1 μM ( Figure 4A ). At higher concentrations, CC214-1 caused an increase in the sub-G 0 population. Myeloma cells treated with rapamycin showed a similar cell cycle arrest ( Figure 4B ), confirming previous studies and suggesting a role of mTORC1 in the control of cell cycle progression (39) . We also analyzed actively cycling cells using BrdU incorporation assays. There was no incorporation of BrdU after CC214-1 treatment in the cell lines tested ( Figure 4C ). In contrast, BrdU incorporation was only partially inhibited by rapamycin treatment in the same cell lines.
We also tested the effect of CC214-1 and rapamycin on cell proliferation in an ex vivo model using freshly isolated bone marrow cells from myeloma patients. The percentage of PCs from patients that incorporated BrdU was very low, as previously reported (40); however, a substantial decrease in BrdU-incorporating PCs after being treated with CC214-1 was observed in all the patient samples tested ( Figure 4D ). In general, rapamycin also blocked the incorporation of BrdU in PCs, but to a lesser extent than CC214-1 treatment. These results indicated that both agents acted on the cell cycle, however CC214-1 blocked cell cycle progression more efficiently than rapamycin.
At the molecular level, we found an increase in p27 protein after CC214-1 treatment in all the cell lines tested ( Figure 5A ). Besides, coimmunoprecipitation experiments indicated an increased association of CDK2, Cyclin E and Cyclin A to p27 in CC214-1 treated cells ( Figure 5B ). Moreover, Retinoblastoma (Rb), a key cell cycle "gatekeeper" in the G 1 /S transition, which is hyper-phosphorylated by the CDK2/Cyclin E complex, was dephosphorylated as a result of CC214-1 treatment ( Figure 5A ).
CC214-1-induced apoptosis in MM cells
In addition to the G 0 /G 1 arrest, the PI staining experiments indicated accumulation of cells in sub-G 0 , especially in the MM1S cell line, suggesting that CC214-1 might induce apoptosis ( Figure 4A ). Staining with Annexin V confirmed the induction of apoptosis after treatment with CC214-1 in MM1S and OPM-2 cells ( Figure 6A ). In contrast, treatment with rapamycin failed to induce clear apoptosis in both cell lines ( Figure 6B ). We also tested the ability of CC214-1 to induce apoptosis on PCs from freshly isolated bone marrow samples from myeloma patients. While the response to CC214-1 was variable, we did observe a dose-dependent induction of apoptosis in most of these patient samples ( Figure 6C ).
Mitochondria play a relevant role in apoptotic processes. Several apoptotic stimuli provoke permeabilization of the mitochondrial outer membrane, which allows escape of proapoptotic proteins from the intermembrane space to the cytosol (41) . In addition to cytochrome c, which is involved in caspase-dependent apoptosis, AIF and Endonuclease G may also be released, and these latter two proteins contribute to caspase-independent cell death (42) . Derangement of the mitochondrial outer membrane by CC214-1 was indicated by the analysis of the mitochondrial membrane potential (Δψ m ) using TMRE dye ( Figure 7A ). Moreover, translocation of cytochrome c, Smac/Diablo and AIF was observed after CC214-1 treatment, although that of AIF, to a lesser extent ( Figure 7B ). In addition, cleavage of caspase-3 and PARP was evidenced in MM1S and OPM-2 cells treated with CC214-1 ( Figure 7C ). Using the pan-caspase inhibitor Z-VAD-fmk, we confirmed the involvement of caspase-dependent apoptosis in the action of CC214-1 as there was a protective effect from apoptosis in the presence of this inhibitor ( Figure   7D ). However, the partial inhibition of apoptosis by Z-VAD-fmk indicated the possible existence of caspase-independent apoptotic mechanisms. On the other hand, we confirmed the absence of apoptosis in 
Discussion
This study analyzed the role of the mTOR pathway and its two branches mTORC1 and mTORC2 in the control of MM cell number. Moreover, we explored the value of targeting mTOR with respect to exclusively acting on either of its two signaling branches. This is relevant since some anti-mTOR therapies under clinical evaluation use rapalogs, which are expected to partially target signal outputs from the mTOR route, as they preferentially act on mTORC1. Gene expression data found deregulation of genes involved in the mTOR pathway, especially with an increased expression of S6 protein and decreased Grb10. Moreover, a high frequency of activation of the mTOR pathway in PCs from myeloma patients was detected by flow cytometry techniques. 71% of the cases had activation of this pathway indicated by the phosphorylation of S6 or Akt. Since it has previously been demonstrated that aberrant activation of the mTOR pathway favors tumorigenesis (6) and drug resistance (43) , these myeloma patient cells harboring mTOR activation might hold more tumor formation capacity and, at the same time, could be effectively targeted in therapy. Interestingly, mTOR activation was more frequent in MM patients than in the premalignant stage MGUS, indicating the importance of this route in MM progression and, according to previous reports, pointing to increased activation of Akt along disease evolution (11) . Activation of the mTOR pathway was only detected in malignant PCs, and not in their normal counterparts. However, the percentage of malignant PCs bearing phosphorylated forms of proteins that serve as readouts of mTOR activity was low. This indicates that the population of malignant PCs is heterogeneous, at least with respect to these markers. It is possible that the subpopulation of PCs with active mTOR may correspond to a population with stem-like properties, as has been reported in other malignant tissues (44) . It would be interesting to test this possibility when adequate markers for myeloma stem cells will be available (45) .
The mTOR pathway was also frequently activated in MM cell lines. In them, silencing Rictor, Raptor or mTOR allowed us to evaluate the potential relevance of targeting mTORC1, mTORC2, or both for myeloma therapy. Reducing the activity of the mTORC1 route had major antiproliferative effect than inhibiting the mTORC2 pathway. This is interesting, as it indicates that mTORC1 predominates over In any case, our results indicate that mTOR knockdown had a superior antiproliferative effect than acting on either of the two mTOR branches individually. This finding reveals the importance of mTOR targeting instead of only acting on each of the multiprotein complexes to which mTOR belongs. This conclusion was also supported by pharmacological studies using two different types of mTOR inhibitors, rapamycin and CC214-1. Rapamycin, an allosteric mTOR inhibitor that disrupts the mTOR complex formation, has been used in cancer therapy (14) . Moreover, former studies have indicated that the mTORC1 inhibitor rapamycin showed antimyeloma effect (39) . However, recent studies demonstrated that this drug is unable to completely block the mTOR pathway due to the existence of rapamycin-insensitive components (21, 23) . Because of this limitation, new-generation, active-site mTOR inhibitors have been investigated for potential clinical utility, as is the case of CC214-1. Rapamycin and CC214-1 decreased MTT metabolization, indicative of inhibition of proliferation. However, while rapamycin was more potent than CC214-1, it was less efficient. In fact, rapamycin only partially inhibited cell growth. Biochemically, CC214-1 efficiently inhibited both mTORC1 and mTORC2 routes in myeloma cells. In contrast, rapamycin failed to inhibit the phosphorylation of 4E-BP1 even though it was efficient inhibiting S6 phosphorylation in myeloma cells. These results are in agreement with studies in other cell types which reported that rapamycin inhibited S6 phosphorylation but failed to affect phosphorylation of 4E-BP1 (23, 48) . Moreover, rapamycin treatment provoked an increase in pAkt. This effect may be due to the negative feedback action of mTORC1 exerted over mTORC2, and which may involve the adapter proteins IRS-1 or Grb2 (19, 36) . Therefore, signaling through these rapamycin-insensitive mTOR-derived pathways may explain the escape of a number of cells to the inhibition by rapamycin. Importantly, this fraction of cells was still attacked by CC214-1, indicating the superior potential anticancer activity of active-site inhibitors such as CC214-1 as compared to rapamycin.
Mechanistically, CC214-1 induced cell cycle arrest and apoptosis, whereas rapamycin mainly produced cell cycle arrest, suggesting a role of mTORC2 complex or rapamycin-insensitive mTORC1 actions in survival and programmed cell death inhibition. CC214-1 was more efficient than rapamycin Several conclusions, some of them with therapeutic relevance, may be extracted from our study. Our experiments indicated that mTOR kinase targeting is more relevant, as an antiproliferative strategy, than just targeting mTORC1 or mTORC2 exclusively. This conclusion is supported by the knockdown genetic experiments as well as by the pharmacological data which demonstrated the antitumoral advantage of the active-site mTOR inhibitor CC214-1 over the mTOR allosteric inhibitor rapamcyin. Moreover, the data we obtained challenge the hypothesis of rapamycin as a bona fide mTOR inhibitor, and suggest that active site mTOR inhibitors may be more appropriate to block mTOR function. It will be important to address whether mTOR targeting will be a more efficient anti-MM therapy than using rapalogs in clinical settings.
Finally, while therapies using these mTOR inhibitors appear promising in preclinical MM studies, it will however be necessary to evaluate their degree of toxicity in the clinic. Its amount as well as that of the indicated proteins associated to it was determined by WB. 
